Imunon has confirmed the deprioritization of its COVID-19 vaccine program. With the company’s cash reserves falling below $5 ...

Investors are reminded that Shareholders of record as of August 7, 2025, will receive a 15% stock dividend payment LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a ...

The current quarter introduced the 15% onetime stock dividend and confirmed accelerated site activation for OVATION 3, compared to the previous quarter's focus on initial site readiness and ...

Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient dosed in Phase 3 OVATION 3 Study ...

Imunon, Inc. ( NASDAQ: IMNN) Q2 2025 Earnings Conference Call August 5, 2025 11:00 AM ET Douglas V. Faller - Chief Medical Officer Khursheed Anwer - Executive VP & Chief Scientific Officer Kimberly ...

Analysts expect Imunon to report an earnings per share (EPS) of $-3.09. The market awaits Imunon's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the ...

Imunon, Inc. (($IMNN)) has held its Q2 earnings call. Read on for the main highlights of the call. The recent earnings call for Imunon, Inc.

Imunon (NASDAQ:IMNN) is scheduled to announce Q2 earnings results on Tuesday, August 5th, before market open. The consensus EPS Estimate is -$4.99. Over the last 1 year, IMNN has beaten EPS estimates ...

Learn about the latest advancements in immunotherapy research focusing on harnessing IL-12 for the treatment of ovarian cancer to potentially improve survival rates.

The OVATION-3 trial is designed to provide an early readout in HRD and BRCA1/2-mutated ovarian cancer patients, ideally leading to rapid filing and approval.